Journal: Frontiers in Endocrinology

Article Title: Unveiling the TrkA-p35/CDK5 axis: a novel therapeutic target in diabetic kidney disease

doi: 10.3389/fendo.2026.1791283

Figure Lengend Snippet: HG-induced TrkA phosphorylation is associated with podocyte inflammation and injury. (A–D) Representative western blots show the levels of (A) TrkA and phospho-TrkA (Tyr490); (B) ERK, phospho-ERK and EGR1; (C) p35 and CDK5; and (D) IL-1β and TNF-α in MPC5 cells from the LG, HG, and LG + Man groups at 24 h (E) Representative immunofluorescence double staining shows the expression of phospho-TrkA (Tyr490) and synaptopodin in MPC5 cells from the LG, HG, and LG + Man groups. ****p < 0.0001. p < 0.05 was considered statistically significant; ns indicates not significant.

Article Snippet: Antibodies against TrkA (Cat. No. 2505), Cdk5 (Cat. No. 2506), and p35/25 (Cat. No. 2680) were purchased from Cell Signaling Technology (Danvers, MA, USA).

Techniques: Phospho-proteomics, Western Blot, Immunofluorescence, Double Staining, Expressing

Journal: Frontiers in Endocrinology

Article Title: Unveiling the TrkA-p35/CDK5 axis: a novel therapeutic target in diabetic kidney disease

doi: 10.3389/fendo.2026.1791283

Figure Lengend Snippet: TrkA inhibitor suppresses p-TrkA-mediated upregulation of ERK, EGR1, and p35 in the MPC5 cells grown under HG conditions. Representative western blots show the levels of (A) TrkA and phospho-TrkA (Tyr490), (C) ERK, phospho-ERK, and EGR1, and (E) CDK5 and p35 in the LG, HG+Vehicle (0.1% DMSO), HG + Inh-TrkA, HG + empty vector, HG + TrkA OE, and HG + TrkA OE + PD98059 groups. Representative western blots show the levels of (B) TrkA and phospho-TrkA (Tyr490), (D) ERK, phospho-ERK, and EGR1, and (F) CDK5 and p35 in the LG, HG+si-NC, HG+si-TrkA, HG + TrkA OE+Ctrl, and HG + TrkA OE + GW441756 groups. *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001. p < 0.05 was considered statistically significant.

Article Snippet: Antibodies against TrkA (Cat. No. 2505), Cdk5 (Cat. No. 2506), and p35/25 (Cat. No. 2680) were purchased from Cell Signaling Technology (Danvers, MA, USA).

Techniques: Western Blot, Plasmid Preparation

Journal: Frontiers in Endocrinology

Article Title: Unveiling the TrkA-p35/CDK5 axis: a novel therapeutic target in diabetic kidney disease

doi: 10.3389/fendo.2026.1791283

Figure Lengend Snippet: TrkA inhibition reduces the levels of p-TrkA, p-ERK, EGR1, p35, and CDK5 in the kidneys of db/db mice. (A–C) Representative western blots show the protein expression levels of (A) TrkA and phospho-TrkA (Tyr490), (B) ERK, p-ERK and EGR1, and (C) p35 and CDK5 in the kidney samples from the control, db/db, Inh-NC, and Inh-TrkA groups of mice. (D) Representative IF images show the expression of Synaptopodin (red) in the glomeruli of control, db/db, Inh-NC, and Inh-TrkA groups of mice (400X). ***p < 0.001. p < 0.05 was considered statistically significant; ns indicates not significant.

Article Snippet: Antibodies against TrkA (Cat. No. 2505), Cdk5 (Cat. No. 2506), and p35/25 (Cat. No. 2680) were purchased from Cell Signaling Technology (Danvers, MA, USA).

Techniques: Inhibition, Western Blot, Expressing, Control

Journal: Frontiers in Endocrinology

Article Title: Unveiling the TrkA-p35/CDK5 axis: a novel therapeutic target in diabetic kidney disease

doi: 10.3389/fendo.2026.1791283

Figure Lengend Snippet: Schematic diagram shows the TrkA/ERK/p35/CDK5 regulatory axis and the site of action for the TrkA inhibitor GW441756 in the murine renal podocytes.

Article Snippet: Antibodies against TrkA (Cat. No. 2505), Cdk5 (Cat. No. 2506), and p35/25 (Cat. No. 2680) were purchased from Cell Signaling Technology (Danvers, MA, USA).

Techniques: